HIV patients had reduced brain volume and poorer cognitive performance.
Patients with HIV treated with cART have lower neuropsychological test scores than controls, but no significant neuropsychological decline over time.
Evaluating the risk factors of neurocognitive decline in HIV.
Effective cognitive screening instruments are needed in order to assess and manage milder forms of HIV-associated neurocognitive disorders.
Early detection and robust treatment are critical to limiting deficits in achieving developmental milestones in HIV-infected infants.
The results indicate HERV-K activation as a potential mechanism for HIV-associated ALS.
For the most part, symptoms tend to subside after treatment initiation.
Until now, it was thought that HIV-related inflammation protected the brain from amyloid deposition.
Paroxetine use improved cognitive impairment and reduced inflammation in HIV patients.
The URMC-099 compound combined with antiretroviral therapy significantly reduced HIV levels.
CSF cultures were negative despite worsening meningitis infection.
Researchers are now testing whether antiretroviral drugs used to treat HIV/AIDS are effective in ALS patients.
The findings may have implications for the development of future vaccines.
The new treatment would need to be combined with other HIV drugs or antibodies.
The brain can harbor active HIV even after seemingly successful antiretroviral treatment.
Some coping strategies like substance abuse may have negative affects on overall health.
Neurology Advisor Articles
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Distinct Clinical Characteristics Associated With Subarachnoid Hemorrhage
- Managing Chronic Pain Associated With Traumatic Brain Injury
- Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Initial Treatment With Ethosuximide Improves Behavioral Outcomes in Childhood Absence Epilepsy
- Bevacizumab Wins Full FDA Approval for Glioblastoma Treatment
- Men With Parkinson Disease More Likely to Have Caregiver
- Diet Linked to Multiple Sclerosis Disability, Disease Severity